Relmada Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$4.15

−0.50%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.33
Previous close: $4.17
Volume: 235,963
Day's high: $4.33
Day's low: $4.09

In brief

Relmada Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $443M.
Its shares closed at $4.17 on 4 Nov 2026, up 50.5% over the past year.
From India you can buy RLMD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Relmada Therapeutics, Inc. (RLMD) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RLMD share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RLMD options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +27.1% (SPY −1.6%, XLV +13.5%). 3 months: −23.3% (SPY −0.4%, XLV +15.5%). 1 year: +50.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RLMD, SPY and XLV · as of 4 Nov 2026
8.5 days to cover short interest
12.2M shares were sold short at the 15 Oct 2026 settlement, 11.4% of the 106.7M shares outstanding; covering them would take 8.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $4.17 was 9.4% above its 50-day average ($3.81) and 22.2% below its 200-day average ($5.36). It has closed below the 200-day for 63 sessions, since 7 Aug 2026. The 50-day average crossed below the 200-day on 1 Sep 2026, 45 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
31% of the way up its 52-week range
Closed at $4.17 on 4 Nov 2026: 47.9% below the 52-week high of $8.00 (6 May 2026) and 72.3% above the low of $2.42 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.6M shares was 1.7× the average of the 30 sessions before it (1.5M), as the price fell 2.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+27.1%

6 months−46.9%

1 year+50.5%

5 years−83.6%

Newswire

About

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Website

Notable moves

April 23, 2025
+82.54%
December 4, 2024
−77.26%
October 13, 2022
−79.57%

Newswire

About

Website

Notable moves

April 23, 2025
+82.54%
December 4, 2024
−77.26%
October 13, 2022
−79.57%

Relmada Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$4.15

−0.50%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $4.33
Previous close: $4.17
Volume: 235,963
Day's high: $4.33
Day's low: $4.09

In brief

Relmada Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $443M.
Its shares closed at $4.17 on 4 Nov 2026, up 50.5% over the past year.
From India you can buy RLMD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Relmada Therapeutics, Inc. (RLMD) shares from India?

Do I need the price of a whole RLMD share to invest?

How much can I invest in US stocks in a year?

Can I trade RLMD options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +27.1% (SPY −1.6%, XLV +13.5%). 3 months: −23.3% (SPY −0.4%, XLV +15.5%). 1 year: +50.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RLMD, SPY and XLV · as of 4 Nov 2026
8.5 days to cover short interest
12.2M shares were sold short at the 15 Oct 2026 settlement, 11.4% of the 106.7M shares outstanding; covering them would take 8.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $4.17 was 9.4% above its 50-day average ($3.81) and 22.2% below its 200-day average ($5.36). It has closed below the 200-day for 63 sessions, since 7 Aug 2026. The 50-day average crossed below the 200-day on 1 Sep 2026, 45 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
31% of the way up its 52-week range
Closed at $4.17 on 4 Nov 2026: 47.9% below the 52-week high of $8.00 (6 May 2026) and 72.3% above the low of $2.42 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.7× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 2.6M shares was 1.7× the average of the 30 sessions before it (1.5M), as the price fell 2.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+27.1%

6 months−46.9%

1 year+50.5%

5 years−83.6%

Newswire

About

Website

Notable moves

April 23, 2025
+82.54%
December 4, 2024
−77.26%
October 13, 2022
−79.57%

Newswire

About

Website

Notable moves

April 23, 2025
+82.54%
December 4, 2024
−77.26%
October 13, 2022
−79.57%

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.5 days to cover short interest

Above its 50-day average, below its 200-day

31% of the way up its 52-week range

Volume 1.7× its 30-session average on 4 Nov 2026

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

8.5 days to cover short interest

Above its 50-day average, below its 200-day

31% of the way up its 52-week range

Volume 1.7× its 30-session average on 4 Nov 2026